GTN is a London-based machine learning startup focused on revolutionizing drug discovery through interdisciplinary innovation, integrating AI and quantum physics.
GTN is a London-based machine learning startup focused on revolutionizing drug discovery through interdisciplinary innovation, integrating AI and quantum physics.
Chief Executive Officer (CEO):
Bill Yde
Chief Technology Officer (CTO):
NA
GTN raised $2.78 million in Seed funding to enhance its drug discovery technology using AI and quantum physics.
Investment firm focused on innovative early-stage businesses.
GTN aims to accelerate drug discovery processes by enhancing its technology and expanding its market reach.
High competition in the biotechnology sector
Navigating regulatory hurdles in the pharmaceutical industry
Collaboration with leading research institutions
Growing demand for innovative drug discovery solutions
GTN raised £2.1 million in Seed funding to advance its AI and quantum physics approach to drug discovery.
Bill Yde's compensation as CEO is under evaluation against GTN's performance and market standards.
Bill Yde
GTN is focused on revolutionizing drug discovery through interdisciplinary innovation using AI and quantum physics.
$2.78 Million
2018-05-10
Octopus Ventures Pentech Entrepreneur First
High competition in the biotechnology sector Navigating regulatory hurdles in the pharmaceutical industry
Collaboration with leading research institutions Growing demand for innovative drug discovery solutions
GTN raised £2.1 million in Seed funding to advance its AI and quantum physics approach to drug discovery. Bill Yde's compensation as CEO is under evaluation against GTN's performance and market standards.
